Form 4: Cartesian Therapeutics CFO Blaine Davis Reports Stock and Option Awards

Blaine Davis, CFO of Cartesian Therapeutics, reports the acquisition of restricted stock units and stock options.

Summary

• On January 2, 2025, Blaine Davis, the Chief Financial Officer of Cartesian Therapeutics, reported transactions involving the company's securities.
• Davis acquired 22,000 shares of common stock through restricted stock units (RSUs) and was granted options to purchase 64,600 shares of common stock.
• The RSUs vest as to 25% on January 2, 2026, with the remainder vesting in three equal annual installments, fully vesting on January 2, 2029.
• The stock options also vest as to 25% on January 2, 2026, with the remainder vesting in three equal annual installments, fully vesting on January 2, 2029.
• Davis also holds options to purchase 103,666 shares of common stock that vested as to 25% on January 2, 2025, with the remainder vesting in three equal annual installments.
• The reported securities amounts have been adjusted to reflect a 1-for-30 reverse stock split that occurred on April 4, 2024.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing detailing stock and option awards to a company executive. It's neutral in tone and reflects routine corporate governance.

Positives

• The grant of RSUs and stock options to the CFO could be seen as an incentive to align his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the CFO.

Future Outlook

The vesting schedules for the RSUs and stock options extend to January 2, 2029, and January 1, 2035, respectively, suggesting a long-term focus for the executive.

Industry Context

Form 4 filings are routine disclosures for corporate insiders and are used to track ownership changes. The granting of stock options and RSUs is a common practice to incentivize executives in the biotech industry.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead, and Biogen routinely grant stock options and restricted stock units to their executives as part of their compensation plans.
• The vesting schedules described in this filing are typical, with vesting occurring over a period of several years to incentivize long-term performance.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs as a positive sign, aligning management's interests with theirs.
• Employees may see this as a standard practice for executive compensation.

Key Dates